Oncology & Cancer

Gilteritinib superior in relapsed, refractory FLT3-mutated AML

(HealthDay)—For relapsed or refractory acute myeloid leukemia (AML) with mutations in the FMS-like tyrosine kinase 3 gene (FLT3), treatment with a selective FLT3 inhibitor, gilteritinib, results in significantly longer ...

Medications

Cocktail proves toxic to leukemia cells

A combination of drugs that affect mitochondria—the power plants inside cells—may become the best weapons yet to fight acute myeloid leukemia, according to Rice University researchers.

Oncology & Cancer

Pediatric cancers: Why some forms of leukemia only affect children

Acute myeloid leukemia (AML) mainly affects children, with often poor prognosis despite several decades of research into more effective treatments. A new study explains why some forms of leukemia develop in very young children ...

Oncology & Cancer

Treating the TOTAL patient: clinical trial reduces relapse

Despite modern therapies, 10% of patients with acute lymphoblastic leukemia (ALL) treated in the U.S. relapse, which dramatically reduces their chance of survival. Results from a St. Jude Children's Research Hospital clinical ...

Genetics

Exploring the risk of ALL in children with Down syndrome

Acute lymphoblastic leukemia (ALL), is the most common childhood cancer. Children with trisomy 21 (Down syndrome) are 10 to 20 times more likely to develop ALL than children without Down syndrome. Historically, children with ...

Oncology & Cancer

Many older patients with AML not receiving active treatment

(HealthDay)—Many older patients with acute myeloid leukemia (AML) do not receive any active treatment, and they have worse survival than those receiving active treatment, according to a study published online Sept. 4 in ...

page 1 from 23